BioSpace News Archive

Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the first quarter ended March 31, 2023.

VolitionRx Limited, a multi-national epigenetics company, announces new research - published in PLOS ONE - which reveals that plasma nucleosome concentrations can be a useful tool for treatment monitoring and disease progression in dogs with hematopoietic cancers.

Asklepios BioPharmaceutical, Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, will deliver 11 presentations offering insights into the research and development of adeno-associated virus therapies for a range of diseases at the American Society of Gene and Cell Therapy 26th Annual Meeting taking place May 16–20, 2023, in Los Angeles, USA.

ESSA Pharma Inc. today announced that the Company will be presenting at the JMP Securities Life Sciences Conference on Tuesday, May 16, 2023 at 10:00 a.m. Eastern Time in New York.

Soligenix, Inc. announced today that the United States (U.S.) Food and Drug Administration (FDA) has granted a Type A meeting to discuss the design of a second, Phase 3 pivotal study evaluating HyBryte™ (hypericin sodium) in the treatment of early stage cutaneous T-cell lymphoma (CTCL), a rare cancer, where it has successfully demonstrated statistically significant results in the first Phase 3 clinical trial.

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today reports its financial results and provides an update on operational progress for the first quarter ended March 31, 2023.

Carisma Therapeutics Inc. (Nasdaq: CARM) (“Carisma” or the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the first quarter ended March 31, 2023 and provided business highlights.

Reneo Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2023 and provided a business update.

Oculis Holding AG announced the nomination of its co-founders, Professors Einar Stefánsson and Thorsteinn Loftsson, as finalists in the ‘Research’ category of the European Inventor Award 2023.

Aerami Therapeutics (“Aerami”) today announced that non-clinical pharmacokinetic data and details of the completed AER-901 Phase 1 trial in healthy volunteers will be presented at the 2023 American Thoracic Society (ATS) International Conference, being held at the Walter E. Washington Convention Center in Washington, D.C. from May 19-24, 2023.